Annual Report

I’m pleased that the “Early diagnosis of AL amyloidosis in Haematology, Cardiology, Neurology , Renal and General clinics: A British Society for Haematology Guideline” was published in May 2026. It provides a practical approach to AL amyloidosis investigations and will be of benefit to a wide group of healthcare professions. 

The guideline for “Management of Myeloma related bone disease” has been submitted to BJH. Two further guidelines: “the Delivery of Bispecific antibody therapy in multiple myeloma” and “Position paper on the management of systemic AL amyloidosis” are also in the final stages and hope to be submitted in the next few months. 

New writing groups are working on the guidelines for “First line treatment of multiple myeloma”, “Optimal laboratory diagnostics for multiple myeloma” and “Supportive care in Multiple Myeloma”. 
 
I would like to thank all authors in the writing groups who selflessly volunteer their time and dedication to produce such high-quality guidelines. 
 

Dr Tracey Chan
Guidelines Chair
March 202